University of Notre Dame
Browse
8,778,360 OCR.pdf (1.71 MB)

Extracellular matrix cancer vaccine adjuvant

Download (1.71 MB)
standard
posted on 2017-06-22, 00:00 authored by Mark A. Suckow, William R. Wolter
Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.

History

Patent Number

US 8,778,360 B2

Other Application

11/583,771

Inventor

Mark A. Suckow William R. Wolter

Inventor from Local Institution

Mark A. Suckow William R. Wolter

Assignee

University of Notre Dame du Lac

Date Modified

2017-06-22

Language

  • English

Claims

19

Prior Publication Number

US 20100233214 A1

Publisher

U.S. Patent and Trademark Office

Cooperative Patent Classification Codes

A61K 39/0011 (20130101); A61K 2039/5152 (20130101); A61K 2039/55511 (20130101)

Contributor

Mark A. Suckow|William R. Wolter

International Patent Classification Codes

A61K 9/00 (20060101); A61K 9/14 (20060101); A61K 9/70 (20060101)

US Patent Classification Codes

424/277.1; 424/423; 424/443; 424/484; 424/489

Usage metrics

    Patents

    Categories

    No categories selected

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC